Table 2.
SPMs’ effects on human macrophages in a cancer context.
| Macrophages | SPMs | Effects | References |
|---|---|---|---|
| Human monocyte-derived macrophages | RvD1 – RvD2 – RvE1 (1pM – 100nM) | Increase phagocytosis of tumor cell debris and reduce pro-inflammatory cytokine secretion | (86) |
| Human monocyte-derived TAM | LX4 (ATL-1) (10nM) | Suppress TAM phenotype Decrease IL-10 secretion |
(165) |
| Human monocyte-derived macrophages | LXA4 - RvD1 – RvD3 (AT-SPM) (100pM-100nM) | Increase phagocytosis of tumor cell debris and reduce pro-inflammatory cytokines secretion | (166) |
| THP-1 monocytes | RvD1-RvD2 (1-100nM) | Suppress TAM phenotype | (167) |
Bold, SPM analogs or receptor agonists.